Accelerated Approval of Elevidys (SRP-9001) for Children with DMD

Kampanje tas opp
Europäische Arzneimittel-Agentur (EMA)

37 552 Signaturer

Ansvarlig har ikke sendt inn kampanjen

37 552 Signaturer

Ansvarlig har ikke sendt inn kampanjen

  1. Startet 2023
  2. Samlingen er fullført
  3. Innsendt
  4. Dialog
  5. Mislyktes

nyheter

02.11.2023, 15:40

Vermarktungs Name von SRP-9001 (Elevidys) eingefügt


Neuer Titel: Accelerated Approval of SRP-9001Elevidys (SRP-9001) for Children with DMD

Neuer Petitionstext:

Lady's and Gentlemen

As the undersigned of this petition, we would like to speak out in favor of SRP-9001Elevidys (SRP-9001) from Sarepta Therapeutics / Roche being approved quickly in Europe for children with Duchenne muscular dystrophy (DMD) who are able to walk. We believe this approval is urgently needed because every day counts for patients and the fastest possible treatment can mean a significant improvement in the quality of life for patients with DMD.


Unterschriften zum Zeitpunkt der Änderung: 26.896


Bidra til å styrke samfunnsdeltakelsen. Vi ønsker å få dine bekymringer hørt samtidig som vi forblir uavhengige.

Markedsfør nå